Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
50 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Biodesix, Inc.’s names, not what it holds today.
Patents granted
50
50 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and 4 in 2023
Applications published
56
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Medical technology5
Analysis of biological materials5
Computer technology2
Biotechnology1
Electrical machinery, apparatus, energy1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Biodesix, Inc. its own name
US, as the owner printed on each patent
29 publishedBiodesix, Inc. its own name
named as the applicant on its applications, in US
27 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 11, 2025 | 12,247,980 | Compositions, methods and kits for diagnosis of lung cancer | Analysis of biological materials | Biodesix, Inc. |
| Feb 18, 2025 | 12,230,398 | Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods | Medical technology | Biodesix, Inc. |
| Sep 17, 2024 | 12,094,587 | Apparatus and method for identification of primary immune resistance in cancer patients | Analysis of biological materials | Biodesix, Inc. |
| Feb 27, 2024 | 11,913,957 | Compositions, methods and kits for diagnosis of lung cancer | Analysis of biological materials | Biodesix, Inc. |
| Feb 6, 2024 | 11,894,147 | Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings | Medical technology | Biodesix, Inc. |
| Jul 25, 2023 | 11,710,539 | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy | Computer technology | Biodesix, Inc. |
| Apr 4, 2023 | 11,621,057 | Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy | Computer technology | Biodesix, Inc. |
| Feb 28, 2023 | 11,594,403 | Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample | Electrical machinery, apparatus, energy | Biodesix, Inc. |
| Jan 3, 2023 | 11,542,340 | Antibodies targeting pulmonary nodule specific biomarkers and uses thereof | Biotechnology | Biodesix, Inc. |
| Oct 18, 2022 | 11,476,003 | Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings | Medical technology | Biodesix, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 11, 2025 | 2025/0379043 | SENSITIVE AND ACCURATE FEATURE VALUES FROM DEEP MALDI SPECTRA | Electrical machinery, apparatus, energy | Biodesix, Inc. |
| Jun 22, 2023 | 2023/0197426 | PREDICTIVE TEST FOR PROGNOSIS OF MYELODYSPLASTIC SYNDROME PATIENTS USING MASS SPECTROMETRY OF BLOOD-BASED SAMPLE | Electrical machinery, apparatus, energy | Biodesix, Inc. |
| Jan 5, 2023 | 2023/0005621 | Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings | Medical technology | Biodesix, Inc. · patent 11,894,147 granted from it |
| Oct 27, 2022 | 2022/0341939 | PREDICTIVE TEST FOR IDENTIFICATION OF EARLY STAGE NSCLC STAGE PATIENTS AT HIGH RISK OF RECURRENCE AFTER SURGERY | Analysis of biological materials | Biodesix, Inc. |
| Aug 18, 2022 | 2022/0259680 | SARS CoV-2 INFECTIVITY DETERMINATION ASSAY | Biotechnology | Biodesix, Inc. |
| Jun 16, 2022 | 2022/0189638 | Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings | Medical technology | Biodesix, Inc. · patent 11,476,003 granted from it |
| Jun 16, 2022 | 2022/0188701 | INTERPRETATION OF MACHINE LEARNING CLASSIFICATIONS IN CLINICAL DIAGNOSTICS USING SHAPELY VALUES AND USES THEREOF | Medical technology | Biodesix, Inc. |
| Jun 2, 2022 | 2022/0170938 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER | Analysis of biological materials | Biodesix, Inc. · patent 12,247,980 granted from it |
| Apr 7, 2022 | 2022/0108771 | Classifier Generation Methods and Predictive Test for Ovarian Cancer Patient Prognosis Under Platinum Chemotherapy | Computer technology | Biodesix, Inc. · patent 11,621,057 granted from it |
| Jan 27, 2022 | 2022/0026416 | METHOD FOR IDENTIFICATION OF CANCER PATIENTS WITH DURABLE BENEFIT FROM IMMUNOTEHRAPY IN OVERALL POOR PROGNOSIS SUBGROUPS | Medical technology | Biodesix, Inc. |
What it applied for, 2024 to 2025: Electrical machinery, apparatus, energy 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.